# moderate to severe rheumatoid arthritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis

> No upcoming FDA catalysts in moderate to severe rheumatoid arthritis; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2024 | [Simponi® (simponi) topline data readout](https://sec-api.dev/pdufa/simponi) | ALVO | moderate to severe rheumatoid arthritis | completed, positive | "In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and the reference product Simponi® in patients with moderate to severe rheumatoid arthritis (clintrials.gov/study/NCT05842213)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325007451/exh_991.htm)) |
| Apr 2024 | [Aria® (golimumab) topline data readout](https://sec-api.dev/pdufa/golimumab) | ALVO | moderate to severe rheumatoid arthritis | completed, positive | "In April 2024 Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and Simponi® (golimumab) in patients with moderate to severe rheumatoid arthritis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325006012/exh_993.htm)) |
| Oct 2025 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | moderate to severe rheumatoid arthritis | completed, positive | "•In October 2025, AbbVie announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of Rinvoq compared to Humira in adult patients with moderate to severe rheumatoid arthritis (RA), who had an inadequate response or intolerance to a single TNF inhibitor other than Humira." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)) |

## Drugs

- [Simponi® (simponi)](https://sec-api.dev/pdufa/simponi) (ALVO)
- [Aria® (golimumab)](https://sec-api.dev/pdufa/golimumab) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate to severe rheumatoid arthritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis

```bibtex
@misc{secapidev_indications_moderate_to_severe_rheumatoid_arthritis_20261116,
  title        = {moderate to severe rheumatoid arthritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_rheumatoid_arthritis_20261116","title":"moderate to severe rheumatoid arthritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
